In the future, combination treatments including therapies targeting the immunosuppressive TME, such as the polarization of macrophages from pro-tumoral M2 TAMs to anti-tumoral M1 TAMs, could represent a promising approach, especially in HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.